Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Ofatumumab in Previously Untreated CLL/SLL
NCT03280160Phase 2Unknown
- Sponsor
- Fundación PETHEMA
- Start
- Sep 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and ofatumumab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Fundación PETHEMA. Primary endpoint: Overall Response Rate at 18 months. Status: unknown.
02
Drugs
ibrutinibofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03280160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280160.